Podcast episode 147 (in German)
Cerebrolysin – 70 years of pig brain extract and an open question
November 24, 2026
For more than 70 years, an extract from pig brain has been used for dementia and after stroke, from Austria to Russia and China. Clinics report good results, so does a well-conducted rehab study — and yet nobody has answered the most important question to this day.
What it is about
Cerebrolysin is not a single active substance but a mixture: pig brain tissue broken down by enzymes into short protein chains and amino acids, developed from 1949 in Innsbruck and still manufactured at Lake Attersee today. In Austria it is prescription-only, in the US it is not approved, and for Germany the research found no approval. The episode goes through what clinics, a large registry collection and a well-designed rehab study show, and sets this against the independent Cochrane analysis. Added to this is what people from the nootropics scene report in surveys, as reports and not as evidence of efficacy, what was found in an ampoule bought online and why animal studies were retracted. At the end there is one question to ask before ordering: Was this tested in people like you or in people after a stroke?
Key points
- A rehab study with 208 people after stroke, double-blind against saline, found after 90 days what the authors called a large advantage in arm function; it was exploratory in design and paid for by the manufacturer.
- A collection from 16 countries published in 2025, with 1,769 people after moderately severe stroke, around 1,000 of them on Cerebrolysin, showed more independence after 90 days; the doctors had chosen who received it, and the manufacturer paid.
- In 2023, Cochrane found in 7 randomized trials with 1,773 people probably no difference in survival; whether people were able to manage on their own again afterwards was not reported by any of the 7 trials.
- Non-fatal serious events occurred more than twice as often in the Cochrane analysis; an analysis from 2021 with 12 trials and 2,202 people, by contrast, found 7.9 percent in both groups.
- In a 2016 survey from nootropics forums with 850 responses, 22 people had tried Cerebrolysin; almost one in four gave it 10 out of 10, the average was 5.6, so mid-table.
- In 2015, a Belgian laboratory found 638 protein fragments in a sample bought on the internet, mainly from the scaffolding of nerve cells, but no fragments of the known growth factors.
- Since early 2025, at least 7 animal studies on Cerebrolysin from 2 laboratories have been retracted, and in Sweden a government body established falsified data; the patient studies are not affected by this.
Where the data stop
For healthy people there is not a single controlled study. Some users feel something distinct, others little, and nobody knows whether that is memory or alertness. A survey of 402 medical students in Romania, which asked about piracetam and Cerebrolysin together, found sleep problems more often among users; the Austrian prescribing information itself mentions a drive-enhancing effect and, rarely, restlessness and insomnia. Nobody checks what is sold online as an ampoule.
After stroke, too, the main question remains open. A European guideline from 2021 recommends the drug for early rehabilitation; among its authors are several who have themselves worked on Cerebrolysin studies, and it asks about early recovery, whereas Cochrane asks about survival and independence. A large, independent study that measures whether people can climb the stairs on their own again could settle this. In case of seizures or severe kidney disease, the prescribing information rules out the drug or advises caution; after a stroke, the treatment team decides.
Listen (in German)
Listen on Spotify Listen on Apple Podcasts Listen on Amazon Music
Published on November 24, 2026.
The topic in the database
- A mixture of neurotrophic peptides with randomized multicenter trials on Alzheimer’s and stroke, approved as a medicine in several countries –Cerebrolysin
All episodes in the app (German)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Content as of: 2026-09-25.